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Abstract Worldwide, gastric cancer is one of the most
common and fatal cancers. The majority of patients present
with an advanced stage of disease. Even with use of pal-
liative chemotherapy most patients die within 1 year after
diagnosis. Medical psychological attention after a diagno-
sis of incurable cancer is focused on end of life support.
This paper presents the care of a patient treated with pal-
liative intent with chemotherapy for an irresectable histo-
logically conﬁrmed gastric cancer. When, unexpectedly
prolonged symptom free survival followed, the reaction of
the patient came as a surprise to the attending medical
team. In this case history we urge those who care for
incurable cancer patients, that the rare patient who survives
against all odds may require special psychological care.
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Background
Gastric cancer is one of the most common and fatal can-
cers, affecting more males than females. Large differences
exist in the incidence of gastric cancers between various
geographic regions. In North America, Africa, Oceania
4–10/100,000 people per year are affected, in northeast
Asia up to 69 cases per 100,000 people per year are
affected (Hartgerink, Jansen, van Grieken & van de Velde,
2009).
It is now known that this cancer is generally the after-
math of Helicobacter Pylori (H. Pylori) infection. The risk
for adenocarcinoma is 6-fold increased in those infected
with H. Pylori. H. Pylori is a bacterium which can lead to
chronic gastritis. However only a minority of patients
infected with this organism develop cancer, concerting risk
factors are high salt intake, low intake of vegetables or
fruit, obesity and smoking (Helicobacter Cancer Collabo-
rative Group 2001). There are two distinct histological
types of gastric adenocarcinoma. The intestinal type of
gastric cancer affects more males and older age groups.
The diffuse type of gastric cancer is equally frequent in
both sexes and more common in younger age groups, and
has a worse prognosis than the intestinal type.
Although the incidence of gastric cancer is declining due
to preventive strategies, such as treatment of H. Pylori and
better food preservation methods, it remains the second
leading cause of cancer related death worldwide. Symp-
tomatic patients often have complaints like weight loss,
abdominal pain or dysphagia. Diagnosis is established by
endoscopy, which is insertion of a ﬂexible tube through the
mouth (Hartgerink et al., 2009). Once the diagnosis is
established by obtaining tissue scored by the pathologist as
being malignant, therapy can be aimed at cure or be limited
to some prolongation of life and mitigation of symptoms.
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Because of the high recurrence rate after surgery alone
most patients are also treated with some form of adjuvant
(postoperative) or neoadjuvant (preoperative) chemother-
apy, in the United States combined with radiotherapy. If
surgery can be done pre-operative measures require CT
scanning and often ultrasound (Hartgerink et al., 2009).
Sometimes it is only during surgery that it becomes clear
that the cancer has progressed beyond the surgeon’s
domain. In such advanced stages of gastric cancer, when
the tumor has become irresectable, attention has to be
focused on palliative measures. The emphasis in this phase
is based on prolonging survival with preservation or
improving quality of life. Care is then largely determined
by the expectancy of approaching death. Although still a
demanding clinical task, much literature and guidance is
available for the clinician on giving optimal support.
Compared to best supportive care, several studies have
described a beneﬁcial effect of chemotherapy on quality of
life, next to achievement of survival beneﬁt. Compared to
mono chemotherapy agents, combination chemotherapy
gives additional survival beneﬁt of some weeks to months,
at the expense of more toxicity (Wagner et al., 2006). With
the development of targeted agents against molecular
signaling pathways a larger survival beneﬁt might be
accomplished. Targeted therapy is a type of medication
which blocks the growth of cancer cells by interfering with
speciﬁc targeted molecules needed for tumor growth rather
than interfering with rapidly dividing cells in the case of
traditional chemotherapy (Hartgerink et al., 2009).
Next to chemotherapy or local palliative measurements
physicians get trained in guiding patients on their way to
approaching death, by listening to their complaints, desires
and fears. Surprisingly little is known about the psycho-
logical consequences for the rare patient with unexpected
long-term survival or cure against all odds, as described
here.
Case Report
A middle-aged married woman was referred after explor-
ative laparotomy because of irresectable intestinal type
adenocarcinoma of the stomach. Until then she had an
active social life, participated in labor with pleasure and
enjoyed spending time with her grandchildren. Chemo-
therapy was instituted, but stopped because of excessive
toxicity. The message communicated to her and her hus-
band at that moment was gloomy based on the initial
diagnosis and the residual lesions on CT-scan after che-
motherapy. Even more than before the start of chemo-
therapy, the patient at the age of 61 expected to die from
this cancer and seemed to adapt to this situation, especially
since a second opinion, conﬁrmed the initial diagnosis and
did not provide alternatives. However the patient remained
in an excellent condition throughout the following years.
Although one could assume that a patient would be
relieved by being an exceptional long-term survivor,
7 years by now, the opposite occurred. Survival became a
considerable psychological problem. Finally some form of
equilibrium was found in a state of denial of ever having
had cancer.
Discussion
The median survival of patients with advanced gastric
cancer is 7–10 months. Chemotherapy can lead to pallia-
tion and prolongs survival with a few months. However
long-term survival or cure after only a partial tumor
remission on chemotherapy without surgery has rarely been
described (Wagner et al., 2006).
Apart from these medical considerations the most
remarkable reaction of our patient was the psychological
one. At ﬁrst the patient accepted the diagnosis of irresec-
table gastric cancer and agreed to palliative chemotherapy.
However, after remaining alive considerably longer than
expected without evidence of disease our patient reacted
with a rare type of denial namely retrospective denial of the
diagnosis.
Denial in cancer patients is a well recognized phenom-
enon in clinical practice (Heim, Augustiny, Schaffner, &
Valach, 1993; Rabinowitz & Peirson, 2006; Sharf, Stelljes,
& Gordon, 2005; Vos & de Haes, 2007). Denial is the
process by which the mind defends itself against painful or
threatening information. Depending on the situation this
can be maladaptive, e.g., leading to treatment delay, or
adaptive, e.g., enabling the patient to cope with this life-
threatening disease. A recent review on denial in cancer
patients distinguished four types of denial: denial of diag-
nosis, denial of impact, denial of affect, and behavioral
escape (Helicobacter Cancer Collaborative Group 2001).
Denial of diagnosis mostly takes place early in the process,
and decreases over time, although it sometimes increases
during the terminal phase (Heim et al., 1993).
Our patient, however, seems to be cured and denying
having had cancer at ﬁrst sight seems incomprehensible.
Insight in this denial can be obtained from available
knowledge on how people try to explain unpredictable life
events. In general, people make different causal attribu-
tions for positive and negative events. Positive events
mostly are considered to be the result of internal causes:
people tend to ascribe success in life to themselves. Neg-
ative events are mostly attributed to external causes: failure
due to circumstances. So, we could expect that our patient
would attribute being a survivor of cancer to these internal
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patients will make causal attributions to external sources
for the fact that they got cancer, clearly a negative event, in
such a way that self-esteem is preserved (Sharf et al.,
2005).
When our patient stayed alive longer than expected
external, rather than internal attributions were sought by
the patient. The patient appeared to begin to believe that
given the fact that the doctors were wrong about dying
soon they could be wrong in other aspects of the disease
too. If the patient did not believe in divine intervention,
how could this unexpected outcome be explained? The
thought of not having cancer in the ﬁrst place is in accor-
dance with this unexpected outcome. Moreover, this con-
viction serves well to reduce anxiety and uncertainty about
recurrence of cancer: a predominant preoccupation in most
survivors of cancer (Rabinowitz & Peirson, 2006; Vos &
de Haes, 2007). There was no reason to be afraid that the
cancer could come back if it had never been there!
Although denial in this case is not a logical solution, it
certainly is a psychological one. Thus for the patient the
past experiences with life-threatening disease and the
unexpected positive outcome are explained, and the fear of
a recurrence of cancer is superﬂuous.
As a medical team we were unable to help the patient on
the path from the certainty of death to unexpected survival.
Whether the adaptation through denial of the patient to the
new situation is the most desirable one is doubtful. Reali-
zation by us that good news may be as difﬁcult to cope with
as bad news might have provided a guideline for earlier
psychological intervention.
Dialogue between Drs. Siemerink (junior Medical
Oncologist), Dr. Jaspers (Psychologist) and Professor
Mulder (senior Medical Oncologist) regarding the case:
Drs. Siemerink: Professor Mulder, how often have you
observe unexpected prolonged survival among patients
with advanced disease? And is there in your opinion a
common reaction in your patients to that situation?
Professor Mulder: There are various levels of unex-
pected survival, most often reported in the context of some
form of alternative medicine. In a review in our country
some 400 reports of that kind were analyzed and only 2
could be accepted as undoubtful. If we give a prognosis of
8–12 months for a patient as described here we would
expect an occasional patient to live for 2 years, just as
some patients with breast cancer may survive for decades
with metastatic disease. However for a patient treated in a
palliative context to be cured, as in this situation, I can
remember three such cases in a period of some 30 years, all
of them were extremely grateful, if not to me at least to
their good fortune.
Professor Mulder: Dr. Jaspers, the reaction of our
patient to survival, retrospective denial of the diagnosis of
cancer, came as a complete surprise for the medical team.
Is this reaction common in cancer patients?
Dr. Jaspers: Denial in cancer patients is a well recog-
nized phenomenon in clinical practice, especially denial of
diagnosis. However, it mostly takes place early in the
process of diagnosis, and decreases over time. Sometimes
it increases during the terminal phase. So, denial is a
common reaction to bad news. What makes denial excep-
tional in this case, is that it is a reaction to the good news of
survival. Other causal attributions for this positive event
could be expected. People normally attribute positive
events to internal causes, in the case of cancer survival for
instance to their ﬁghting spirit or to their change of life-
style. When a patient attributes his survival to his own
behavior or characteristics, there is no need to deny the fact
that he had cancer.
Drs. Siemerink: At ﬁrst we did not understand the
reaction of the patient who was very angry at us and was
convinced that we had failed as doctors and caused much
sorrow.
Dr. Jaspers: Indeed, at ﬁrst sight it seems incompre-
hensible that a positive progress of the disease made the
patient react this way. But from the point of view of the
patient, if it would be true that cancer had never been there
the emotions can be understood. In the patient’s mind, the
patient was told that this disease was fatal and treated
invasively for a disease which was not there.
Drs. Siemerink: So, the retrospective denial of the
diagnosis is a way of coping with this unexpected positive
course of the disease?
Dr. Jaspers: Cancer is a disease that brings much
uncertainty and loss of control for patients. In general there
is little they can do, except rely on medical treatment and
hope for the best. Loss of control is hard to deal with, and
research on coping with cancer shows that at least half of
the surviving patients experience positive effects (post-
traumatic growth) of having cancer. Some consider these
positive effects as a way of coping to regulate feelings of
anxiety and depression (illusionary growth), others con-
sider these positive experiences as real growth (Zoellner &
Maercker, 2006). Retrospective denial of the diagnosis is
an effective way to regain control and at the same time
eliminate anxiety and uncertainty about recurrence of
cancer.
Professor Mulder: At the other hand, denial as a way of
coping seems unrealistic. Can denial be an effective coping
method?
Dr. Jaspers: Denial is the process by which the mind
defends itself against painful or threatening information.
Mostly denial does not last long, because it is only tem-
porarily necessary to regulate and control negative emo-
tions. In the long run denial is often inadequate, because it
hampers adaptation to the altered situation, for instance
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denial can be an adequate or inadequate coping strategy. In
the case of this patient denial not only explains the unex-
pected cure of cancer, but also seems to have positive
effects on the long run (reduce anxiety about recurrence of
cancer). So, may be in this case denial is not a bad strategy
for the patient as long as this strategy has no evident dis-
advantages for the patient. There may be another reason for
this unexpected attribution. In general, people have a
strong urge to seek causal attributions for their behavior or
for the events they experience. The cure of irresectable
gastric cancer cannot be explained. It is hard for people to
live with such events of vital importance that cannot be
explained. So, retrospective denial of the diagnosis makes
sense, because it explains the inexplicable: it is better to
have an improbable explanation than no explanation at all.
Drs. Siemerink: What can we learn from this case? The
reaction of the patient resulted in premature loss of contact
with the patient. We realized too late that the good news
was difﬁcult to cope with.
Dr. Jaspers: Indeed, the ﬁrst lesson to learn from this
case is that good news may be as difﬁcult to cope with as
bad news. To realize this and to speak with the patient
about this unexpected progress and the possible confusing
impact of it can be the ﬁrst step. To share feelings with the
patient over this positive, but unlikely development can
give the physician the opportunity to consider whether
psychological intervention is indicated. Doubts about the
diagnosis can be discussed earlier by the patient when he
feels he is free to do so without direct rejection of this
possibility. I think, physicians should respect this opinion
of the patient, baring in mind that this attribution has a
psychological function. Direct attempts to refute this
opinion only increases resistance to chance or reconsider-
ation of this opinion and hinders discussion of other issues
for example how to adapt to the fact that life is not over yet
and how the patient can plan for the future again. Perhaps,
for some physicians the conviction of the patient that the
diagnosis was wrong is a difﬁcult one, because their
expertise is called in question. Of course, the patient has
the right to be informed about all aspects of his disease, but
sometimes the truth of the medical team is not the truth of
the patient.
Dr. Jaspers: how are you as a young oncologist trained
in dealing with these difﬁcult situations of providing
information about the fatal course of a disease in general
but also staying focused on the individual patient?
Drs. Siemerink: In our training much attention is paid to
communication of bad news and the different ways a
patient can react to this news at diagnosis, for example by
patient simulation and watching videos. However this
speciﬁc situation of sustained denial was not discussed in
my training in its place.
Professor Mulder: If we had recognized the problem
earlier, and had consulted a psychologist, would he have
tried to reverse this process? In other words, given that the
patient has reached some form of equilibrium, can we
consider this to be a satisfactory situation? Not quite
unconnected is the question if it is likely that at some time
the patient will realize that cancer indeed had occurred.
Dr. Jaspers: I don’t think the reason for consulting a
psychologist should be to convince the patient of the cor-
rectness of the diagnosis of cancer, but to explore with the
patient what contrary to all expectations, this unexpected
survival means for the patient. I think it is important for the
patient to express (mixed) emotions and to talk about the
reactions to this confusing course of the disease.
Undoubtedly, in talking about the situation the question
will arise: ‘How can this be?’ It is hard to speculate whe-
ther this patient would have considered other answers than
the conviction that cancer never had occurred, but I sup-
pose that earlier in the process this idea is still more open
for discussion. When the patient is still looking for an
answer, the psychologist can explain that it is our human
nature to attribute causes to all important events that we
experience, also the events that perhaps are inexplicable.
So, it may be difﬁcult to realize that certainty about the
cause of progress of the patient’s disease cannot be found.
But, if the patient is already convinced that the doctor was
wrong in his diagnosis, I think it would be wise to respect
this opinion, given the psychological function that we
discussed before. This does not mean the psychologist has
to agree with the patient: he can state that—just like the
medical team—he cannot give an explanation for this
unexpected development. What the psychologist can do for
the patient is to sort out how to adapt to this new situation,
prevent obsessive preoccupation and rumination, and how
to get on with life, leaving this stressful period of illness
behind. When the patient succeeds in this respect, the
urgency to blame the physicians for the alleged faults they
made will be less, and the conclusion that the patient was
very lucky in the end can be acceptable.
Drs. Siemerink: Finally a question that, perhaps, cannot
be answered: should this extraordinary case change the
information we give an incurable patient or if there is no
statistical hope should we still provide it?
Dr. Jaspers: In the last decades there has been a major
change in the way we talk about cancer and in our view
how to inform the patient. Although the patient has the
(legal) right to be informed fully, sometimes the truth and
nothing but the truth can be too much to handle for the
patient. Appraisal of the state of mind of the patient can be
difﬁcult and to bring the bad news of approaching death
remains a demanding clinical task, but in general the
information available should be given. Timing, choosing
the right words and opportunity are important in telling the
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beloved ones the opportunity to deal with it. So, when there
is no (statistical) hope, no false hope should be given.
When the patient needs hope to endure his situation, he will
ﬁnd it anyway, holding back the truth is not a good way to
provide hope.
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